Parker, Waichman, Alonso LLP

YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)


AddThis Social Bookmark Button

Injured by Serevent?

David Graham, the FDA researcher who questioned Vioxx's safety before it was recalled has recently raised safety concerns about Serevent. Recently a warning was added to Serevent concerning asthma-related fatalities in studies. Data from a large placebo-controlled US study that compared the safety of Serevent (Generic: Salmeterol) and a placebo showed an increase in asthma-related deaths in patients receiving Serevent. In patients taking Serevent there were 13 deaths out of 13,176. In patients taking the placebo there were only 3 of 13,179.

An older study showed 36 patients taking Serevent died from asthma or had life-threatening attacks. Some patients taking Serevent have had trouble breathing and required intubations, the insertion of a tube into the throat forcing open the airways. Serevent is an aerosol spray. Patients usually use it twice a day to prevent asthma attacks.

Serevent Label Update
The label for Serevent has been updated with a warning stating that the drug can increase the chance of severe asthma attacks that can result in death. The Food & Drug Administration (FDA) made this announcement on May 16, 2006.

If you or a loved one took Serevent and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
SereventRSS Feed

FDA Panel Wants Restrictions on Two Asthma Drugs

Dec 12, 2008 | Parker Waichman Alonso LLP
A U.S. Food and Drug Administration (FDA) panel has called for restrictions on two asthma treatments:  Serevent and Foradil.  Both belong to a class  of drugs known as long-acting beta-agonists.  Both contain a drug that relaxes muscles around airways, said WHEC TV, but may also mask symptoms that can prompt deadly asthma attacks.  Although the expert 27-member panel found Serevent and Foradil drugs present greater risks than benefits and should not be used in the...

FDA Considers Heart Risks of Serevent, Foradil, Advair and Symbicort

Dec 11, 2008 | Parker Waichman Alonso LLP
One expert estimates that long-acting beta-agonists (LABAs)  - a class of asthma drugs that includes Serevent, Foradil, Advair, and Symbicort - might be responsible for about 14,000 deaths, Reuters is reporting.  The comments were part of a confrontational meeting between the U.S. Food and Drug Administration (FDA) and an advisory panel discussing how to handle increased risks experienced with the inhaled asthma medications called LABAs, said Reuters, LABAs are used by millions of...

Complications, Deaths Seen with Some Long-Acting Asthma Drugs

Dec 5, 2008 | Parker Waichman Alonso LLP
Some asthma drugs in a class  known as long-acting beta agonists (LABA) can increase the risk of death and complications, a new Food & Drug Administration (FDA) analysis has found.  The analysis looked at GlaxoSmithKline PLC's Serevent and Advair, Novartis AG's and Schering-Plough Corp.'s Foradil and AstraZeneca PLC's Symbicort.The FDA analysis was prepared for an advisory committee meeting next week that is slated to discuss the safety of the drugs, The Wall Street Journal...

Asthma Med Serevent Linked to Serious Adverse Events, Death

Jul 18, 2008 | Parker Waichman Alonso LLP
Researchers have just revealed that patients with chronic asthma who take the asthma medication Serevent—also known generically as Salmeterol—on a daily basis are at increased risk for serious adverse events, including deathThe research involved a 12-week review of 32 clinical trials that involved 62,630 patients.  In addition to pointing to serious adverse events with daily Serevent use, the research findings also suggest that the collaborative use of inhaled corticosteroids...

FDA Seeks Info on Serevent, Advair, Foradil As Part of Safety Review

Mar 6, 2008 | Parker Waichman Alonso LLP
Asthma drugs, including  Serevent, Advair, Foradil, are the subject of a Food & Drug Administration (FDA) safety review.  The FDA has requested information from the manufacturers of the asthma medications as part of an ongoing safety review of the drugs in children. Serevent, Advair and Foradil are long-acting beta 2-adrenergic agonists  that  prevent the release of substances in the body that cause inflammation of airways in the lungs. In 2005, the FDA...

More Serevent News

Serevent
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

What condition was this medication prescribed to treat?

Please explain whether asthma attacks worsened after taking Serevent and whether they required hospitalization or intubation:

Please further describe side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Social Security Disability | Contact
Statement of Clients' Rights | Site Map | Drug Injury Search | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome | Florida Personal Injury Law Firm

© 2002-2009 YourLawyer.com®. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News